NasdaqGS - Nasdaq Real Time Price USD

Apellis Pharmaceuticals, Inc. (APLS)

20.08

+0.87

+(4.53%)

At close: May 1 at 4:00:01 PM EDT

20.87

+0.79

+(3.93%)

Pre-Market: 4:31:36 AM EDT

High Growth Tech Stocks In The US For May 2025

As the U.S. market experiences a notable upswing, with the S&P 500 and Nasdaq Composite marking gains amid strong earnings reports from major tech companies like Microsoft and Meta, investors are keenly observing how these developments impact high-growth tech stocks. In this environment of robust AI spending and positive sentiment, identifying companies with solid financials and innovative strategies becomes crucial for those looking to tap into the potential of high-growth sectors.

Simply Wall St. 15 hours ago

RNG

APLS
+4.53%

ARDX
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

RYTM
-2.13%

APLS
+4.53%
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of

GlobeNewswire yesterday

APLS
+4.53%
Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?

We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC’s […]

Insider Monkey 2 days ago

APLS
+4.53%
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

APLS
+4.53%

ARVN
-24.84%
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

Insider Monkey 8 days ago

APLS
+4.53%
Apellis Announces Craig Wheeler to Join the Board of Directors

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. “We are thrilled to welcome Craig to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph

GlobeNewswire 10 days ago

APLS
+4.53%
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 16 days ago

APLS
+4.53%
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Zacks 29 days ago

APLS
+4.53%

NVS
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

The sNDA application is based on the positive outcomes from the Phase III VALIANT trial at week 26.

Pharmaceutical Technology 30 days ago

APLS
+4.53%
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription

GlobeNewswire 30 days ago

APLS
+4.53%
Exploring US High Growth Tech Stocks In March 2025

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.

Simply Wall St. last month

ENFN

CMRX

APLS
+4.53%
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better […]

Insider Monkey last month

APLS
+4.53%
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s (APLS) Empaveli to differentiate itself. The firm highlights that Fabhalta is indicated for adults with C3G, and is indicated to reduce proteinuria. Moreover, the label explicitly states that outcomes have not been established in post-transplant patients. Morgan Stanley says that overall, the restric

TipRanks last month

NVS

NVSEF

APLS
+4.53%
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million. JP Morgan maintains the Overweight rating with a price forecast of $54. Analyst Anupam Rama says Apellis’ lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematolog

Benzinga last month

APLS
+4.53%
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.

Zacks last month

APLS
+4.53%
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals ( NASDAQ:APLS ) Full Year 2024 Results Key Financial Results Revenue: US$781.4m (up 97% from FY...

Simply Wall St. last month

APLS
+4.53%
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth driven by SYFOVRE, while navigating market challenges and advancing its development pipeline.

GuruFocus.com 2 months ago

APLS
+4.53%
Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

APLS
+4.53%
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

APLS
+4.53%

Performance Overview

Return	APLS	S&P 500 (^GSPC)
YTD	-37.07%	-4.72%
1-Year	-56.40%	+11.67%
3-Year	-53.87%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Apellis Pharmaceuticals, Inc. (APLS)

High Growth Tech Stocks In The US For May 2025

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Apellis Announces Craig Wheeler to Join the Board of Directors

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Exploring US High Growth Tech Stocks In March 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Q4 2024 Apellis Pharmaceuticals Inc Earnings Call

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Performance Overview